Christopher J Sweeney
Overview
Explore the profile of Christopher J Sweeney including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
236
Citations
7227
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sweeney C, Bottoms M, Kaushik R, Aderjan E, Sherborne N
Environ Toxicol Chem
. 2025 Feb;
PMID: 39987504
The Organisation of Economic Co-operation and Development (OECD) 216 nitrogen transformation test is used to understand the impacts of plant protection products (PPPs) on the soil microbiome. However, there is...
2.
Azad A, Kostos L, Agarwal N, Attard G, Davis I, Dorff T, et al.
Eur Urol
. 2025 Feb;
PMID: 39947976
Background And Objective: The treatment landscape for advanced prostate cancer has evolved significantly over the past decade. The introduction of docetaxel, androgen receptor pathway inhibitors (ARPIs), poly(ADP-ribose) polymerase inhibitors, and...
3.
Dean A, Nelson J, Jones A, Sykes A, Child F, Sweeney C, et al.
Sci Total Environ
. 2025 Feb;
966:178726.
PMID: 39923471
Acid mine drainage (AMD) is a frequent cause of ecological damage to many river and estuarine habitats. Once AMD pollution is halted our understanding of subsequent habitat recovery requires long-term...
4.
van Hall B, Sweeney C, Bottoms M, van Gestel C
Environ Toxicol Chem
. 2025 Feb;
44(2):524-533.
PMID: 39919230
The European environmental risk assessment (ERA) of pesticides to soil invertebrates applies a correction factor (CF) of 2 to endpoints derived from toxicity tests with lipophilic pesticides (log Kow >...
5.
Conduit C, Inderjeeth A, Allen R, Martin A, Parulekar W, Mulroe E, et al.
Future Oncol
. 2025 Jan;
21(6):627-636.
PMID: 39819293
No abstract available.
6.
Ravi P, Xie W, Gillessen S, Tombal B, Spratt D, Nguyen P, et al.
Prostate Cancer Prostatic Dis
. 2025 Jan;
PMID: 39779964
Background: Patients treated with RT and long-term androgen deprivation therapy (ltADT) for high-risk localized prostate cancer (HRLPC) with 1 high-risk factor (any of Gleason ≥8, PSA > 20 ng/mL, ≥cT3;...
7.
Markowski M, Ren Y, Tierney M, Royce T, Yamashita R, Croucher D, et al.
Eur Urol Oncol
. 2024 Dec;
PMID: 39665917
Background And Objective: Owing to the expansion of treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and an appreciation of clinical subgroups with differential prognosis and treatment responses, prognostic and...
8.
Mostaghel E, Mostaghel E, Wang V, Marck B, Sharifi N, Matsumoto A, et al.
Endocr Relat Cancer
. 2024 Nov;
32(2).
PMID: 39588946
The CHAARTED study showed that adding docetaxel (Doc) to androgen deprivation therapy (ADT) in men initiating treatment for metastatic hormone-sensitive prostate cancer (mHSPC) prolongs survival, particularly in high-volume disease. Androgens...
9.
Morel K, German B, Hamid A, Nanda J, Linder S, Bergman A, et al.
J Clin Invest
. 2024 Nov;
135(2.
PMID: 39560993
Phenotypic plasticity is a hallmark of cancer and is increasingly realized as a mechanism of resistance to androgen receptor-targeted (AR-targeted) therapy. Now that many prostate cancer (PCa) patients are treated...
10.
Gillessen S, Turco F, Davis I, Efstathiou J, Fizazi K, James N, et al.
Eur Urol
. 2024 Oct;
87(2):157-216.
PMID: 39394013
Background And Objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The...